Cancer Family
Thymus Neoplasm
CI-CAN-00000366Explore in graph →
Non-malignant104 active trials1 approved drugs1 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000366Explore in graph →
Clinical trials
283 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03375320 | Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors | active not recruiting | Phase 3 | 298 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT04759586 | Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma | active not recruiting | Phase 3 | 244 | National Cancer Institute (NCI)NIH | 4 | Sep 10, 2026 | clinicaltrials |
| NCT05918302 | Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.(LEVEL) | recruiting | Phase 3 | 170 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 4 | May 12, 2026 | clinicaltrials |
| NCT02633514 | Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma | withdrawn | Phase 3 | 0 | Fudan UniversityOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06402708 | Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3) | recruiting | Phase 3 | 172 | Fudan UniversityOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT02014805 | Postoperative Conformal Radiotherapy for Stage II-III B Type Thymoma | unknown | Phase 3 | 210 | Chinese Academy of Medical SciencesOTHER | 1 | Jul 16, 2020 | clinicaltrials |
Data updated 4 days agoSource updated Sep 22, 2026source: clinicaltrials